Abbott Laboratories vs. Zentalis Pharmaceuticals, Inc. Common Stock
ABT
Abbott Laboratories
$111.59 -2.20%
VS ZNTLZentalis Pharmaceuticals, Inc. Common Stock
$3.88 -0.26%
Abbott Laboratories (ABT) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| ABT | ZNTL | |
|---|---|---|
| Market Cap | $193.09 billion | $367.33 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-139,545,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | ZNTL | |
|---|---|---|
| P/E Ratio | 36.11 | — |
| Price / Book | 3.73 | 2.56 |
| Price / Sales | 4.14 | — |
ZNTL leads on 1 of 1 valuation factors.
Profitability
| ABT | ZNTL | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | -97.15% |
ABT leads on 1 of 1 profitability factors.
Dividend
| ABT | ZNTL | |
|---|---|---|
| Dividend Yield | 2.26% | — |
| Payout Ratio | 81.55 | — |
ABT and ZNTL split the dividend factors evenly.
Risk & Sentiment
| ABT | ZNTL | |
|---|---|---|
| Short Interest | 0.57% | 0.64% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, ZNTL overview, ZNTL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.